Trial Profile
Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Penpulimab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 18 Jan 2023 New trial record